TY  - JOUR

T1  - Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.

JO  - Journal of Clinical Oncology

UR  - https://doi.org/10.1200/jco.2025.43.5_suppl.659

PY  - 2025/02/10

AU  - Galsky MD

AU  - Van Der Heijden MS

AU  - Catto JWF

AU  - Al-Ahmadie H

AU  - Meeks JJ

AU  - Nishiyama H

AU  - Drakaki A

AU  - Vu TQ

AU  - Antonuzzo L

AU  - Atduev V

AU  - Kann AG et al

ED  - 

DO  - DOI: 10.1200/jco.2025.43.5_suppl.659

PB  - American Society of Clinical Oncology (ASCO)

VL  - 43

IS  - 5_suppl

SP  - 659

EP  - 659

Y2  - 2025/04/05

ER  -